Yıl: 2021 Cilt: 8 Sayı: 4 Sayfa Aralığı: 359 - 364 Metin Dili: Türkçe DOI: 10.14744/nci.2020.26504 İndeks Tarihi: 21-01-2022

Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey

Öz:
OBJECTIVE: Hepatitis B virus (HBV) infection remains a global public health problem. Among its modes of transmission, vertical transmission from mother to child during pregnancy is exceedingly important. This study investigated seropositivity for hepatitis B surface antigen (HBsAg) among pregnant women aged 16–49 years and their pregnancy outcomes in several health institutions (university and state hospitals, family health centers) from seven cities in Turkey. METHODS: An Excel form was sent to the sites participating in the study, and the total number of pregnant women who were tested for HBsAg between 2010 and 2017, HBsAg positivity rates, and the ages of HBsAg-positive pregnant women was collected retrospectively. Serum samples were obtained from 204,865 pregnant women from four regions between 2010 and 2017, including 107,463 from Black Sea, 2306 from Marmara, 48,339 from East Anatolia, and 46,757 from Aegean. HBsAg levels were determined on automated devices using chemiluminescence. RESULTS: In the study, the data of 204,865 pregnant women from seven different provinces (Afyonkarahisar, Erzurum, Istanbul, Izmir, Manisa, Mus, and Rize) in different geographical regions were accessed, and HBsAg positivity was found in 2343 pregnant women (1.14%). The highest HBsAg seroprevalence was found in women who were older 26–40 years/1977–1991 birth year range on average. In the data of the present study, the number of pregnant women with HBsAg positivity among pregnant women born after the initiation of the national vaccination program and catch-up vaccination program is only 124 and constitutes 5.3% of all HBsAg-positive pregnant women CONCLUSION: In this study, it has been found that HBsAg positivity in pregnant women has been decreasing in Turkey and that it is significantly lower, especially in those born after the initiation of the national vaccination program. Continuation of national neonatal HBV vaccination with high compliance is very important.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546–55.
  • 2. World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. Vaccine 2019;37:223–5.
  • 3. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016;388:1081–8.
  • 4. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599–603.
  • 5. Aslam A, Campoverde Reyes KJ, Malladi VR, Ishtiaq R, Lau DTY. Management of chronic hepatitis B during pregnancy. Gastroenterol Rep (Oxf ) 2018;6:257–62.
  • 6. Aktuğ-Demir N, Asan A, Ayaz C, Çelen MK, Köse Ş, et al. Management of chronic hepatitis B in pregnancy: a consensus report of the study group for viral hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases. Klimik Journal 2013;26:12–9.
  • 7. European Association for the study of the liver (EASL) 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Available at: https://easl.eu/wp-content/uploads/2018/10/ HepB-English-report.pdf. Accessed Apr 17, 2020.
  • 8. Anderson S, Harper LM, Dionne-Odom J, Halle-Ekane G, Tita ATN. A decision analytic model for prevention of hepatitis B virus infection in Sub-Saharan Africa using birth-dose vaccination. Int J Gynaecol Obstet 2018;141:126–32.
  • 9. The Immunological basis for immunization series - Module 22: Hepatitis B. Available at: https://www.who.int/immunization/documents/ ISBN_978_92_4_150475_1/en/. Accessed Jan 15, 2019.
  • 10. Centers for Disease Control and Prevention (2019). Perinatal transmission. Available at: https://www.cdc.gov/hepatitis/hbv/perinatalxmtn.html. Accessed Jan 16, 2019.
  • 11. Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2018;67:1–31.
  • 12. WHO vaccine-preventable diseases: monitoring system. 2018 global summary. http://apps.who.int/immunization_monitoring/globalsummary. Accessed Jan 21, 2019.
  • 13. Karaca N, Karaca Ç. Prevention of mother-to-child transmission of HBV. In: Ozaras R, Tahan V, editors. Viral hepatitis: chronic hepatitis B. Springer, Cham; 2018. p. 65–70.
  • 14. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. http://www.who.int/hepatitis/strategy2016-2021/ ghss-hep/en/. Accessed Apr 17, 2020.
  • 15. Ott JJ, Stevens GA, Wiersma ST. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis 2012;12:131.
  • 16. Su WJ, Chen SF, Yang CH, Chuang PH, Chang HF, Chang MH. The impact of universal infant hepatitis B immunization on reducing the hepatitis B carrier rate in pregnant women. J Infect Dis 2019;220:1118–26.
  • 17. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 1996;276:906–8.
  • 18. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855–9.
  • 19. World Health Organization. Global policy report on the prevention and control of viral hepatitis - in WHO member states. Geneva: World Health Organization; 2013. Available at: https://www.who.int/hepatitis/publications/global_report/en/. Accessed Mar 23, 2021.
  • 20. Tosun S. Dünyada ve Türkiye’de viral hepatit B epidemiyolojisi. In: Rahmet Güner, Tabak F, editros. Viral Hepatit 2018. Viral Hepatitle Savaşım Derneği. İstanbul: İstanbul Medikal Sağlık ve Yayıncılık; 2018. p.13–48.
  • 21. Tabak F, Yurdaydın C, Kaymakoğlu S, Akarsu M, Akıncı EG, Akkız H, et al; Guidelines Study Group VH. Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. Turk J Gastroenterol 2017;28:73–83.
  • 22. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21:1020–6.
  • 23. Mıstık R. Türkiye’de viral hepatit epidemiyolojisi - Yayınların irdelenmesi. In: Tabak F, Balık İ, Tekeli E, editors. Viral Hepatit. Viral Hepatitle Savaşım Derneği. İstanbul: İstanbul Medikal Yayıncılık; 2007. p. 9–50.
  • 24. Bakar RZ, Dane B. Gebelerde hepatit B seropozitifliği ve Türk literatürüne bir bakış. Perinatal Journal 2016;24:83–8.
  • 25. Aynıoglu A, Aynıoglu O, Akar T, Aydın M, Altunok ES. HBsAg, anti-HBs and anti-HCV seropositivity rates among pregnant women attending a university hospital in Zonguldak. Viral Hepat J 2015;21:31– 4.
  • 26. Furuncuoglu Y, Bolukbas FF, Bolukbas C, Torun P, Ozturk R. Changes in the prevalence of HBV infection in pregnant women in Turkey between 1995 and 2015: a 20-year evaluation. Postgrad Med J 2016;92:510–3.
  • 27. The Ministry of Health of Turkey. Health Statistics Yearbook. 2010. Available at: http://sbu.saglik.gov.tr/ekutuphane/kitaplar/saglikistatistikleriyilligi2010.pdf. Accessed Jan 31, 2019.
  • 28. Ay P, Torunoglu MA, Com S, Çipil Z, Mollahaliloğlu S, Erkoc Y, et al. Trends of hepatitis B notification rates in Turkey, 1990 to 2012. Euro Surveill 2013;18:20636. Erratum in: Euro Surveill 2014;18:pii/20653.
  • 29. Temel R. Doğu ve Güneydoğudan göç eden bireylerin yoksulluk ve sosyal dışlanma boyutunda incelenmesi (Manisa ili örneği). Denizli: Pamukkale Üniversitesi Sosyal Bilimler Enstitüsü Yüksek Lisans Tezi Çalışma Ekonomisi ve Endüstri İlişkileri Ana Bilim Dalı Yüksek Lisans Tezi; 2017. Available at: http://acikerisim.pau.edu.tr:8080/ xmlui/bitstream/handle/11499/1394/Ramazan%20Temel.pdf?sequence=1&isAllowed=n. Accessed Mar 25, 2021.
  • 30. Türkiye Viral Hepatit Önleme ve Kontrol Programı (2018-2023). Available at: https://hsgm.saglik.gov.tr/depo/birimler/Bulasici-hastaliklar-db/duyurular/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_ Programi/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_Programi_ TR.pdf. Accessed Apr 15, 2020.
APA Bayındır Bilman F, Tosun S, YILDIZ I, Alay H, EVRENOS A, KUTLU H, Cakar Z, Kesli R, BAKTIR ALTUNTAŞ S, Altuntaş B (2021). Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. , 359 - 364. 10.14744/nci.2020.26504
Chicago Bayındır Bilman Fulya,Tosun Selma,YILDIZ ILKNUR ESEN,Alay Handan,EVRENOS AYSE NUR,KUTLU HÜSEYİN HAYDAR,Cakar Zeynep sule,Kesli Recep,BAKTIR ALTUNTAŞ Sibel,Altuntaş Bülent Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. (2021): 359 - 364. 10.14744/nci.2020.26504
MLA Bayındır Bilman Fulya,Tosun Selma,YILDIZ ILKNUR ESEN,Alay Handan,EVRENOS AYSE NUR,KUTLU HÜSEYİN HAYDAR,Cakar Zeynep sule,Kesli Recep,BAKTIR ALTUNTAŞ Sibel,Altuntaş Bülent Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. , 2021, ss.359 - 364. 10.14744/nci.2020.26504
AMA Bayındır Bilman F,Tosun S,YILDIZ I,Alay H,EVRENOS A,KUTLU H,Cakar Z,Kesli R,BAKTIR ALTUNTAŞ S,Altuntaş B Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. . 2021; 359 - 364. 10.14744/nci.2020.26504
Vancouver Bayındır Bilman F,Tosun S,YILDIZ I,Alay H,EVRENOS A,KUTLU H,Cakar Z,Kesli R,BAKTIR ALTUNTAŞ S,Altuntaş B Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. . 2021; 359 - 364. 10.14744/nci.2020.26504
IEEE Bayındır Bilman F,Tosun S,YILDIZ I,Alay H,EVRENOS A,KUTLU H,Cakar Z,Kesli R,BAKTIR ALTUNTAŞ S,Altuntaş B "Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey." , ss.359 - 364, 2021. 10.14744/nci.2020.26504
ISNAD Bayındır Bilman, Fulya vd. "Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey". (2021), 359-364. https://doi.org/10.14744/nci.2020.26504
APA Bayındır Bilman F, Tosun S, YILDIZ I, Alay H, EVRENOS A, KUTLU H, Cakar Z, Kesli R, BAKTIR ALTUNTAŞ S, Altuntaş B (2021). Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. İstanbul Kuzey Klinikleri, 8(4), 359 - 364. 10.14744/nci.2020.26504
Chicago Bayındır Bilman Fulya,Tosun Selma,YILDIZ ILKNUR ESEN,Alay Handan,EVRENOS AYSE NUR,KUTLU HÜSEYİN HAYDAR,Cakar Zeynep sule,Kesli Recep,BAKTIR ALTUNTAŞ Sibel,Altuntaş Bülent Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. İstanbul Kuzey Klinikleri 8, no.4 (2021): 359 - 364. 10.14744/nci.2020.26504
MLA Bayındır Bilman Fulya,Tosun Selma,YILDIZ ILKNUR ESEN,Alay Handan,EVRENOS AYSE NUR,KUTLU HÜSEYİN HAYDAR,Cakar Zeynep sule,Kesli Recep,BAKTIR ALTUNTAŞ Sibel,Altuntaş Bülent Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. İstanbul Kuzey Klinikleri, vol.8, no.4, 2021, ss.359 - 364. 10.14744/nci.2020.26504
AMA Bayındır Bilman F,Tosun S,YILDIZ I,Alay H,EVRENOS A,KUTLU H,Cakar Z,Kesli R,BAKTIR ALTUNTAŞ S,Altuntaş B Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. İstanbul Kuzey Klinikleri. 2021; 8(4): 359 - 364. 10.14744/nci.2020.26504
Vancouver Bayındır Bilman F,Tosun S,YILDIZ I,Alay H,EVRENOS A,KUTLU H,Cakar Z,Kesli R,BAKTIR ALTUNTAŞ S,Altuntaş B Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. İstanbul Kuzey Klinikleri. 2021; 8(4): 359 - 364. 10.14744/nci.2020.26504
IEEE Bayındır Bilman F,Tosun S,YILDIZ I,Alay H,EVRENOS A,KUTLU H,Cakar Z,Kesli R,BAKTIR ALTUNTAŞ S,Altuntaş B "Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey." İstanbul Kuzey Klinikleri, 8, ss.359 - 364, 2021. 10.14744/nci.2020.26504
ISNAD Bayındır Bilman, Fulya vd. "Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey". İstanbul Kuzey Klinikleri 8/4 (2021), 359-364. https://doi.org/10.14744/nci.2020.26504